Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLATO-dose: Clopidogrel Dose in Overweight CAD
NCT01509365Phase 4Completed
- Sponsor
- Les Laboratoires des Médicaments Stériles
- Start
- Dec 2011
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clopidogrel in coronary artery disease (CAD) (3 arms), sponsored by Les Laboratoires des Médicaments Stériles. Primary endpoint: Cardiac death or non-fatal myocardial infarction or ischemia-driven target vessel revascularisation at 6 months. Started Dec 2011; status: completed.
02
Drugs
clopidogrel
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT01509365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01509365.